TolerogenixX expands Phase II immune-tolerance trial and closes EUR 12 million Series A financing
06 juil. 2023 04h00 HE
|
AKAMPION
Ongoing Phase IIb study expands to arm B5-year results of phase I study confirm efficacy and safety of novel immune-tolerance inducing cell therapy in organ transplantationSecond closing of Series A...
Medical Biomimetics Industry Research 2023
19 juin 2023 09h18 HE
|
Research and Markets
Dublin, June 19, 2023 (GLOBE NEWSWIRE) -- The "Medical Biomimetics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027" report has been added to ...
Organ Transplant Rejection Medication Market to Surpass USD 7.0 Billion by 2031, Propelled by Remarkable CAGR of 3.9% | Transparency Market Research
07 juin 2023 13h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, June 07, 2023 (GLOBE NEWSWIRE) -- The global organ transplant rejection medication market is estimated to flourish at a CAGR of 3.9% from 2023 to 2031. According...
Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference
02 juin 2023 08h00 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will present...
Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results
11 mai 2023 16h01 HE
|
Eledon Pharmaceuticals, Inc.
Reported open-label data from ongoing Phase 1b trial of tegoprubart in kidney transplantation demonstrating mean eGFRs from 3 participants above 70 mL/min/1.73m2 at measured timepoints Completed...
Global Organ Transplant Diagnostics Market to 2033: Rise in Incidence of Chronic Diseases Leading to Organ Failure Increases the use of Transplant Diagnostics
11 mai 2023 04h33 HE
|
Research and Markets
Dublin, May 11, 2023 (GLOBE NEWSWIRE) -- The "Organ Transplant Diagnostics Market - A Global and Regional Analysis: Focus on Offering, Application, Technology, Transplant Type, End User, and Country...
Eledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
04 mai 2023 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it plans to release financial results for the first quarter ended March...
Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
01 mai 2023 07h00 HE
|
Eledon Pharmaceuticals, Inc.
$35 million in upfront financing with the potential to receive additional aggregate financing up to $105 million, subject to achieving clinical development milestones, plus up to $45 million upon...
Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology
31 mars 2023 06h00 HE
|
Eledon Pharmaceuticals, Inc.
Results from three participants demonstrated no incidence of acute rejection at durations of 56, 154, and 232 days Strong graft function observed in all three participants with mean eGFRs above 70...
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results
30 mars 2023 16h01 HE
|
Eledon Pharmaceuticals, Inc.
`Four patients enrolled in open-label Phase 1b kidney transplant trial with clinical data on first three patients to be presented at the World Congress of Nephrology (WCN) on March 31, 2023 Safety...